Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment
Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment
Recruiting · NCT03868722 · Registry updated 2023-12-04Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment | B-cell chronic lymphocytic leukemia | Recruiting | Phase 2 / Phase 3 | 2023-12-04 | NCT03868722 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Albert Schweitzer Hospital | Dordrecht | Netherlands | 1 |
| Herlev og Gentofte Hospital | Herlev | Denmark | 5 |
| Ikazia Hospital (Ikazia Ziekenhuis) | Rotterdam | Netherlands | 1 |
| Karolinska University Hospital | Stockholm | Sweden | 15 |
| Rigshospitalet | Copenhagen | Denmark | 141 |
| Sjællands universitetshospital Roskilde | Roskilde | Denmark | 2 |
| Örebro University Hospital | Örebro | Sweden | 5 |